Aromatic sulfone hydroxamates and their use as protease inhibitors
申请人:——
公开号:US20040010019A1
公开(公告)日:2004-01-15
This invention is directed to aromatic sulfone hydroxamates (also known as “aromatic sulfone hydroxamic acids”) and salts thereof that, inter alia, inhibit matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. This invention also is directed to a prevention or treatment method that comprises administering such a compound or salt in an MMP-inhibiting and/or aggrecanase-inhibiting effective amount to an animal, particularly a mammal having (or disposed to having) a pathological condition associated with MMP and/or aggrecanase activity.
Disclosed are soluble diarylmethanofullerene derivatives that are effective as acceptors for organic thin-film solar batteries. They help to constitute effective organic thin-film solar batteries.
3-(n-heterocyclyl)-pyrrolidinyl-phenyl-oxazolidinones as antibacterial agents
申请人:Ferrer Internacional, S.A.
公开号:EP2141162A1
公开(公告)日:2010-01-06
The invention provides new oxazolidinone compounds of formula (I) wherein R, R1, R2 and R3 have different meanings.
Preparative processes, pharmaceutical compositions, and uses thereof in the treatment of bacterial infections are also provided.
Process for manufacturing of enantiomerically pure 3-hydroxy-3-phenyl-propylamin
申请人:Baumgarten Wolfgang
公开号:US20060009533A1
公开(公告)日:2006-01-12
The present invention relates to an improved process for preparing enantiomerically pure 3-hydroxy-3-phenyl-propylamines on an industrial scale using asymmetrical hydrogenation as a key step and optionally a special sequence of subsequent steps, using a catalyst system consisting of rhodium and chiral 4-(dicyclohexylphosphino)-2-(diphenyl-phosphino-methyl)-N-methyl-aminocarbonyl-pyrrolidine.
3-cyanopyrrolidinyl-phenyl-oxazolidinones as antibacterial agents
申请人:Ferrer Internacional, S.A.
公开号:EP2141161A1
公开(公告)日:2010-01-06
The invention provides new oxazolidinone compounds of formula (I) wherein R1, R2 and R3 have different meanings.
Preparative processes, pharmaceutical compositions, and uses thereof in the treatment of bacterial infections are also provided.